Across TCGA pan-cancer cohorts, RPL18AP17 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RPL18AP17 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RPL18AP17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL18AP17 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.
KIRC, OV, and ESCA are the cancer types where RPL18AP17 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.